
Though the precise etiology is unknown, the striking similarity between benign prostatic hyperplasia (BPH) prostate treatment and the embryonic morphogenesis of the prostate has paved way for the hypothesis that BPH may result from a reawakening in adulthood of embryonic induction processes. The enlarged gland is said to contribute to the lower urinary tract symptoms complex. The restriction of the flow of urine from the bladder tends to cause symptoms such as nocturia, intermittency, urgency, hesitancy and decreased stream. If left untreated, BPH may lead to bladder or kidney damage, urinary tract infections, bladder stones or incontinence. These insights are according to the report titled, "Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028," which has been freshly added to Market Research Hub's (MRH) ever-expanding repository. Medication has been the most prevalent treatment to contain or moderate the symptoms of prostate enlargement. As such, medications such as alpha blockers, 5-alpha reductase inhibitors have grown in traction. The former, which includes doxazosin, alfuzosin, tamsulosin and silodosin generally work quickly in mean with comparatively small prostates. The latter, which includes dutasteride and finasteride is also growing in traction. Though minimally invasive is not recommended if patients have an untreated UTI, a urethral stricture disease or Parkinson's disease, behind all odds, it is rising in popularity. With rising number of patients suffering from bladder stones, urinary tract obstruction and blood in the urine, companies are augmenting the availability of minimally invasive treatment.